Haruki Jimbo

Haruki Jimbo

Auto-generated profile, based on publicly available information

Haruki Jimbo

Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
DHDenitsa M. Hristova
Denitsa M. Hristova
TFTakeshi Fukumoto
Takeshi Fukumoto
CTChihiro Takemori
Chihiro Takemori
LGLe Gao
Le Gao
XHXia Hua
Xia Hua
MHMeenhard Herlyn
Meenhard Herlyn
The upregulation of the adaptor protein NUMB triggers melanocytic differentiation from multipotent skin stem cells, which share many properties with aggressive melanoma cells. Although NUMB acts as a tumor suppressor in various human cancer types, little is known about its role in melanoma. In this study, we investigated the role of NUMB in melanoma progression and its regulatory mechanism. Analysis of The Cancer Genome Atlas melanoma datasets revealed that high NUMB expression in melanoma tissues correlates with improved patient survival. Moreover, NUMB expression is downregulated in metastatic melanoma cells. NUMB knockdown significantly increased the invasion potential of melanoma cells in a three-dimensional collagen matrix in vitro and in the lungs of a mouse model in vivo; it also significantly upregulated the expression of the NOTCH target gene CCNE. Previous studies suggested that Wnt signaling increases NUMB expression. By mimicking Wnt stimulation through glycogen synthase kinase-3 inhibition, we increased NUMB expression in melanoma cells. Furthermore, a glycogen synthase kinase-3 inhibitor reduced the invasion of melanoma cells in a NUMB- dependent manner. Together, our results suggest that NUMB suppresses invasion and metastasis in mela- noma, potentially through its regulation of the NOTCH–CCNE axis and that the inhibitors that upregulate NUMB can exert therapeutic effects in melanoma.

1 April 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
XWXuebing Wang
Xuebing Wang
CCClaire Yik-Lok Chung
Claire Yik-Lok Chung
AYAi Yoshioka
Ai Yoshioka
SHShinya Hashimoto
Shinya Hashimoto
HJHaruki Jimbo
Haruki Jimbo
KNKen-Ichi Noma
Ken-Ichi Noma

13 October 2021 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
MOM. Ohata
M. Ohata
TFTakeshi Fukumoto
Takeshi Fukumoto
Takashi HashimotoTakashi Hashimoto
Takashi Hashimoto
CTC. Takemori
C. Takemori
HJH. Jimbo
H. Jimbo
CNC. Nishigori
C. Nishigori

1 February 2021 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
RMRyosuke Mochizuki
Ryosuke Mochizuki
YOYumi Oka
Yumi Oka
SHShinya Hashimoto
Shinya Hashimoto
ESErina Shiraki
Erina Shiraki
MOMariko Ogo
Mariko Ogo
CNChikako Nishigori
Chikako Nishigori

8 February 2021 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Open access
PDF file
RKRina Koizumi
Rina Koizumi
TFTakeshi Fukumoto
Takeshi Fukumoto
HJHaruki Jimbo
Haruki Jimbo
CNChikako Nishigori
Chikako Nishigori
Intravenous immunoglobulins (IVIg) are increasingly being used to treat a wide spectrum of dermatological and neurological autoimmune diseases. Although the administration of IVIg does not usually result in severe adverse reactions, side effects of IVIg reportedly occur in 6‐13% of patients. Most reported cases were not severe, and IVIg is considered a relatively safe drug. Some reports described a vesicular eczematous eruption caused by IVIg that was cured by applying topical steroid ointments or systemic steroids. Herein, we present, to the best of our knowledge, the first case of severe vesicular eczematous eruption all over the body induced by IVIg that was unresponsive to topical steroid ointment and was subsequently treated with narrow band‐ultraviolet B (NB‐UVB) therapy successfully. NB‐UVB was started at a dose of 400 mJ/cm2 once a week, and swift improvement was observed. The skin rash disappeared in the first 2 months, and the pathogenesis of IVIg‐induced eczematous eruption remains unelucidated. No change in eosinophils and complement levels were observed in our case. Given the increase in the widespread use of IVIg, we have shown that NB‐UVB therapy is a candidate choice for the treatment of IVIg‐induced severe vesicular eczematous eruption.

20 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
XWXuebing Wang
Xuebing Wang
CCClaire Yik-Lok Chung
Claire Yik-Lok Chung
AYAi Yoshioka
Ai Yoshioka
SHShinya Hashimoto
Shinya Hashimoto
HJHaruki Jimbo
Haruki Jimbo
KNKen-Ichi Noma
Ken-Ichi Noma
Angiosarcoma is an aggressive soft-tissue sarcoma with a poor prognosis. Chemotherapy for this cancer typically employs paclitaxel, one of the taxanes (genotoxic drugs), although it has a limited effect due to chemoresistance for prolonged treatment. Here we examine a new angiosarcoma treatment approach that combines chemotherapeutic and senolytic agents. We first find that the chemotherapeutic drugs, cisplatin and paclitaxel, efficiently induce cellular senescence of angiosarcoma cells. Subsequent treatment with a senolytic agent, ABT-263, eliminates senescent cells through the activation of the apoptotic pathway. In addition, expression analysis indicates that senescence-associated secretory phenotype (SASP) genes are activated in senescent angiosarcoma cells and that ABT-263 treatment eliminates senescent cells expressing genes in the type-I interferon (IFN-I) pathway. Moreover, we show that cisplatin treatment alone requires a high dose to remove angiosarcoma cells, whereas a lower dose of cisplatin is sufficient to induce senescence, followed by the elimination of senescent cells by senolytic treatment. This study sheds light on a potential therapeutic strategy against angiosarcoma by combining a relatively low dose of cisplatin with the ABT-263 senolytic agent, which can help ease the deleterious side effects of chemotherapy.